Laura Iacorossi1, Francesca Gambalunga2, Rosaria De Domenico3, Valeria Serra4, Cristina Marzo5, Paolo Carlini6. 1. IRCCS "Regina Elena" National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy. Electronic address: laura.iacorossi@gmail.com. 2. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier, 1, 00133, Rome, Italy. Electronic address: francescagambalunga.86@gmail.com. 3. IRCCS "Regina Elena" National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy. Electronic address: rosaria-dedomenico@hotmail.com. 4. IRCCS "Regina Elena" National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy. Electronic address: serravaleria_1994@libero.it. 5. IRCCS "Regina Elena" National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy. Electronic address: marzo-cristina@libero.it. 6. Division of Medical Oncology 1, IRCCS "Regina Elena" National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy. Electronic address: paolo_carlini@yahoo.it.
Abstract
PURPOSE: To explore adherence to oral hormone treatment in patients with metastatic prostate cancer (mCRPC) and to identify the factors that influence it. METHODS: A qualitative exploratory study was conducted at the National Cancer Institute of Rome. Patients aged >18 years with castration-resistant prostate cancer (mCRPC) and who were using oral hormone drugs were recruited. Semi-structured interviews were used for data collection, subsequently transcribed verbatim and analysed using Ritchie and Spencer's framework analysis. RESULTS: The sample included 13 patients with a median age of 72 who were treated, on average, for seven months with abiraterone acetate (AA) (76.9%) and enzalutamide (ENZ) (23.1%). Five themes were identified: expression of the concept of adherence, favouring factors, obstacle factors, functional strategies and levels of adherence. CONCLUSIONS: The patients express a good level of adherence, which they define in different ways-the helping relationship with the attending physician, the support of the family members and the few side effects of the drugs. For the future, it is recommended to perform a multicentre mixed method study to explain the levels of adherence and distress in women with breast cancer.
PURPOSE: To explore adherence to oral hormone treatment in patients with metastatic prostate cancer (mCRPC) and to identify the factors that influence it. METHODS: A qualitative exploratory study was conducted at the National Cancer Institute of Rome. Patients aged >18 years with castration-resistant prostate cancer (mCRPC) and who were using oral hormone drugs were recruited. Semi-structured interviews were used for data collection, subsequently transcribed verbatim and analysed using Ritchie and Spencer's framework analysis. RESULTS: The sample included 13 patients with a median age of 72 who were treated, on average, for seven months with abiraterone acetate (AA) (76.9%) and enzalutamide (ENZ) (23.1%). Five themes were identified: expression of the concept of adherence, favouring factors, obstacle factors, functional strategies and levels of adherence. CONCLUSIONS: The patients express a good level of adherence, which they define in different ways-the helping relationship with the attending physician, the support of the family members and the few side effects of the drugs. For the future, it is recommended to perform a multicentre mixed method study to explain the levels of adherence and distress in women with breast cancer.
Authors: Martin J Connor; Mesfin G Genie; David Burns; Edward J Bass; Michael Gonzalez; Naveed Sarwar; Alison Falconer; Stephen Mangar; Tim Dudderidge; Vincent Khoo; Mathias Winkler; Hashim U Ahmed; Verity Watson Journal: Eur Urol Open Sci Date: 2021-12-20
Authors: Yash B Shah; Amy L Shaver; Jacob Beiriger; Sagar Mehta; Nikita Nikita; William Kevin Kelly; Stephen J Freedland; Grace Lu-Yao Journal: Cancers (Basel) Date: 2022-08-03 Impact factor: 6.575